Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, small cell
Stage/Subtype:  extensive stage small cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 35 for your search:
Start Over
Whole-Brain Radiation Therapy with or without Hippocampal Avoidance in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-CC003, NCI-2015-01548, NCT02635009
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-331, NCI-2015-01362, 2015-001097-18, NCT02481830
A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: 59R5-003, NCI-2013-02234, NCT01859741
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA212-115, NCI-2015-01260, 2015-000136-15, NCT02472977
G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: G1T28-02, NCI-2015-01360, NCT02499770
Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: G1T28-03, NCI-2015-01365, NCT02514447
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Cisplatin or Carboplatin and Etoposide With or Without Vandetanib in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer or High-Grade or Poorly Undifferentiated Neuroendocrine Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LUN06-113, NCI-2013-00309, 0712-21, 1011004344, IRUSZACT0083, NCT00613626
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Stereotactic Body Radiation Therapy, Radiofrequency Ablation, and Microwave Ablation in Treating Patients with Inoperable and Recurrent Lung Cancer Near Central Airways
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-08-026, NCI-2010-01669, 10-000656, JCCC-SUPPL-3, NCT01051037
Ponatinib Hydrochloride in Treating Patients with Stage III-IV Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-2002, NCI-2013-01644, PAM004-1, PAM005-2, NCT01935336
Pegylated Irinotecan NKTR 102 in Treating Patients with Refractory Brain Metastasis from Non-small Cell Lung Cancer or Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LUN0067, NCI-2014-02101, 350, 351, NCT02312622
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Trastuzumab Emtansine in Treating Patients with HER2 Amplified or Mutant Advanced Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-335, NCI-2016-00262, NCT02675829
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16015, NCI-2016-00857, 2015-005069-21, I4D-MC-JTJH, NCT02735980
Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1400B, NCI-2014-01379, NCT02154490, NCT02785913
Autologous Cytotoxic T Lymphocytes in Treating Patients With Advanced HER2- Positive Malignancy
Status: Active
Phase: Phase I
Type: Treatment
Age: 3 and over
Trial IDs: H-24486, NCI-2012-00777, NCT00889954
Dose-escalation Study of Oral CX-4945
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Belinostat, Cisplatin, and Etoposide in Treating Patients with Recurrent or Advanced Small Cell Lung Cancer or Neuroendocrine Cancer
Status: Temporarily closed
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0173, NCI-2013-01451, 090173, 09-25-0099, NCI 8238, P09511, 8238, NCT00926640
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8808, NCI-2011-02500, CDR0000700997, UPCI 10-115, NCT01366144
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 200858, NCI-2014-00693, NCT02034123
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4190C00010, NCI-2014-02609, NCT02261220
Start Over